Synapse - Jaclyn Hechtman

Results (55)

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial

Journal Article

Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
Lancet Oncology (2020)

Fulltext@MSK | Save

Microsatellite instability (MSI-H) in metastatic urothelial carcinoma (mUC): A biomarker of divergent responses to systemic therapy

Meeting Abstract

Sarfaty, M.; Teo, M. Y.; Al-Ahmadie, H.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Solit, D. B.; Ratna, N.; Regazzi, A. M.; Hechtman, J. F.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Regorafenib in combination with first-line chemotherapy for metastatic esophagogastric cancer

Journal Article

Moy, R. H.; Dos Santos Fernandes, G.; Jonsson, P.; Chou, J. F.; Basunia, A.; Ku, G. Y.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; more...
The Oncologist (2020)

Fulltext@MSK | Save

Genomic characterization of ERBB2-driven biliary cancer and a case of response to ado-trastuzumab emtansine

Journal Article

Mondaca, S.; Razavi, P.; Xu, C.; Offin, M.; Myers, M.; Scaltriti, M.; Hechtman, J. F.; Bradley, M.; O'Reilly, E. M.; Berger, M. F.; more...
JCO Precision Oncology (2019)

Fulltext@MSK | Save

Real-world outcomes of an automated physician support system for genome-driven oncology

Journal Article

Tao, J. J.; Eubank, M. H.; Schram, A. M.; Cangemi, N.; Pamer, E.; Rosen, E. Y.; Schultz, N.; Chakravarty, D.; Philip, J.; Hechtman, J. F.; more...
JCO Precision Oncology (2019)

Fulltext@MSK | Save

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma

Meeting Abstract

Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer

Meeting Abstract

Mondaca, S.; Walch, H. S.; Nandakumar, S.; Chatila, W. K.; Hechtman, J. F.; Cercek, A.; Diaz, L. A.; Sanchez-Vega, F.; Kemeny, N. E.; Segal, N. H.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma

Meeting Abstract

Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)